AG 1295 是选择性血小板衍生生长因子受体酪氨酸激酶抑制剂。它能抑制 PDGFR 的自磷酸化，对 EGF 受体的自磷酸化无影响。

AG 1295 is a selective platelet-derived growth factor receptor (PDGFR) tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR. But it can not affects the autophosphorylation of the EGF receptor[1][2][3][4].

AG1295 (10 μM, 100 μM) significantly inhibits rabbit conjunctival fibroblast cell growth stimulated by PDGF-AA or PDGF-BB in vitro[2]. AG 1295 inhibits PDGFR autophosphorylation with IC50s of 0.3-0.5 μM and 0.5-1 μM for membrane autophosphorylation assays and Swiss 3T3 cells, respectively[1].

AG-1295 reduces neointimal formation in aortic allograft vasculopathy by inhibition of PDGFR-beta-triggered tyrosine phosphorylation[3]. AG1295 (12 mg/kg; i.p.; daily; for 14 or 21 days) significantly reduces interstitial fibrosis as verified by a smaller Sirius-Red stained area, and by a reduced number of macrophages, and by the ED-A+ fibronectin deposition. It is also verified by the number of cells positive for alpha-smooth muscle actin[4].

71897-07-9

C16H14N2

234.3

DMSO:60 mg/mL (256.08 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years